In the press

Matthew Read comments on Saba’s IEM stake in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on Saba’s IEM stake and other questions in Patrick Brusnahan’s article:

“Given that Saba could not have known how much its fellow shareholders were tendering, how has it very conveniently ended up with 29.9% of IEM post the tender offer, which just avoids it acquiring ‘control’ under the City Code?”

Read the article here